Use of ribaxamase (SYN-004), a β-lactamase, to prevent Clostridium difficile infection in β-lactam-treated patients: a double-blind, phase 2b, randomised placebo-controlled trial -

Use of ribaxamase (SYN-004), a β-lactamase, to prevent Clostridium difficile infection in β-lactam-treated patients: a double-blind, phase 2b, randomised placebo-controlled trial
Information type: Randomised controlled trials
Source: The Lancet Infectious Diseases
Specialities: Gastrointestinal disorders | Infection and infectious diseases | Respiratory disorders
Summary
RCT (n=413) found a lower rate of C difficile infections when using ribaximase with ceftriaxone for treating respiratory tract infections vs ceftriaxone alone (1.0% vs 3.4%, risk reduction 2.4% one-sided p=0.045).
UKMi comment

Ribaxamase inactivates antibiotics in the lumen of the gastrointestinal tract and prevents initial C difficile infection.

A related commentary discusses this research. It states that phase 3 studies are certainly warranted; however, it remains to be seen whether ribaxamase will be equally effective at reducing the risk of colonisation by pathogenic bacteria conferred by other β-lactams.
Related links: Editorial